| |
| |
|
| Insider
Information: |
Smither John W |
| Relationship: |
Director |
| City: |
Calabasas |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
89,084 |
|
|
Indirect Shares
|
176,353 |
|
|
| Direct
Value |
$119,790 |
|
|
|
Indirect Value
|
$1,197,590 |
|
|
| Total
Shares |
265,437 |
|
|
| Total
Value |
$1,317,380 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -84.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Kythera Biopharmaceuticals Inc |
KYTH |
Chief Financial Officer |
2015-10-01 |
0 |
2015-10-01 |
0 |
Premium* |
|
|
Sienna Biopharmaceuticals, Inc. |
SNNA |
|
2019-01-01 |
46,657 |
2019-01-01 |
34,961 |
Premium* |
|
|
Arcutis Biotherapeutics, Inc. |
ARQT |
Chief Financial Officer |
2024-02-13 |
11,365 |
2024-02-13 |
141,392 |
Premium* |
|
|
Effector Therapeutics Ord Shs |
EFTR |
Director |
2021-08-25 |
24,142 |
2021-08-25 |
0 |
Premium* |
|
|
Genelux Corp |
GNLX |
Director |
2023-09-13 |
6,920 |
2023-09-11 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2024-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
11,365 |
11,365 |
0 |
- |
|
| GNLX |
Genelux Corp |
Director |
– • – |
2023-09-13 |
4 |
S |
$20.78 |
$18,702 |
D/D |
(900) |
6,920 |
0 |
% |
|
| GNLX |
Genelux Corp |
Director |
– • – |
2023-09-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
900 |
|
% |
|
| GNLX |
Genelux Corp |
Director |
– • – |
2023-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,920 |
7,820 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial OfficerOfficer |
• – – |
2023-08-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
141,392 |
|
% |
|
| EFTR |
Effector Therapeutics Ord... |
Director |
– • – |
2021-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
24,142 |
24,142 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-03-10 |
4 |
OE |
$1.68 |
$840 |
D/D |
500 |
46,821 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-03-10 |
4 |
AS |
$32.90 |
$16,450 |
D/D |
(500) |
46,321 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-03-10 |
4 |
AS |
$32.90 |
$41,125 |
I/I |
(1,250) |
86,715 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-03-04 |
4 |
OE |
$1.68 |
$20,833 |
D/D |
12,396 |
46,321 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
9,500 |
33,925 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-03-01 |
4 |
AS |
$34.20 |
$26,440 |
D/D |
(773) |
24,425 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-02-10 |
4 |
AS |
$35.64 |
$26,730 |
D/D |
(750) |
25,198 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-02-10 |
4 |
OE |
$1.68 |
$1,260 |
D/D |
750 |
25,948 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-02-10 |
4 |
AS |
$35.64 |
$71,280 |
I/I |
(2,000) |
87,965 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-02-01 |
4 |
AS |
$35.00 |
$131,250 |
I/I |
(3,750) |
89,965 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-02-01 |
4 |
AS |
$35.00 |
$43,750 |
D/D |
(1,250) |
25,198 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-02-01 |
4 |
OE |
$1.68 |
$2,101 |
D/D |
1,250 |
26,448 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-01-19 |
4 |
AS |
$30.00 |
$37,500 |
I/I |
(1,250) |
93,715 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-01-19 |
4 |
OE |
$1.68 |
$840 |
D/D |
500 |
25,698 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2021-01-19 |
4 |
AS |
$30.00 |
$15,000 |
D/D |
(500) |
25,198 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2020-12-14 |
4 |
AS |
$30.00 |
$112,500 |
I/I |
(3,750) |
94,965 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2020-12-14 |
4 |
AS |
$30.00 |
$45,000 |
D/D |
(1,500) |
25,198 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2020-12-14 |
4 |
OE |
$1.68 |
$2,521 |
D/D |
1,500 |
26,698 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Chief Financial Officer |
• – – |
2020-09-29 |
4 |
AS |
$30.00 |
$37,500 |
I/I |
(1,250) |
98,715 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
